(News Bulletin 247) – Jefferies reaffirms its ‘buy’ recommendation and its target price of 120 euros on Sanofi, welcoming the publication of positive phase III data for its flagship drug Dupixent in COPD (chronic obstructive pulmonary disease).

“Dupixent significantly reduced exacerbations and improved lung function, and could thus be the first biologic drug approved for this important market opportunity if the second trial is successful in the first half of 2024,” he said.

The broker specifies that its sales estimate for Dupixent of 20 billion euros by 2031 only includes 0.7 billion for COPD, thus implying the potential for upside for the long-term EPS of the health group in the event of success. .

Copyright (c) 2023 News Bulletin 247. All rights reserved.